Physician profile
Robert D Wallace
NPI 1023075637
$20,694.69
in general payments reported to CMS, 2019-2025
20 companies · $933 in 2025
The $933 reported for 2025 was more than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,003 · 2020: $585 · 2021: $105 · 2022: $51.41 · 2023: $17K · 2024: $630 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Food and Beverage: $1,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,349.00 |
| Food and Beverage | $1,600.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Poriferous LLC | $17,349.00 | 2023 | Su-Por Surgical Implants |
| Sientra, INC. | $668.40 | 2019-2021 | |
| Kls-Martin L.P. | $486.07 | 2019-2020 | |
| Revance Therapeutics, INC. | $341.28 | 2024-2025 | Daxxify |
| Abbvie INC. | $276.02 | 2024-2025 | |
| Mentor Worldwide LLC | $228.06 | 2024-2025 | Mentor Memorygel Resterilizable Gel Sizer, Artoura Breast Tissue Expander |
| Kerecis Limited | $217.52 | 2022-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Access Pro Medical, LLC | $185.35 | 2025 | Matriderm |
| Depuy Synthes Sales INC. | $162.64 | 2020 | |
| Galderma Laboratories, L.P. | $139.19 | 2025 | Dysport |
| Aroa Biosurgery Incorporated | $127.77 | 2024-2025 | |
| Medline Industries Lp | $106.02 | 2019 | |
| Allergan, INC. | $92.47 | 2019 | |
| Polynovo North America LLC | $60.37 | 2024 | Novosorb Btm |
| Sun Pharmaceutical Industries INC. | $57.47 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acera Surgical, INC. | $48.49 | 2021 | |
| Stryker Corporation | $47.62 | 2019 | |
| Organogenesis INC. | $43.26 | 2025 | Novachor |
| Kowa Pharmaceuticals America, INC. | $33.15 | 2022-2023 | Seglentis |
| Misonix INC | $24.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.